Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Velcade
Related studies linked through entity extraction aliases.
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
- Status
- UNKNOWN
- Phase
- PHASE3
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
- Status
- COMPLETED
- Phase
- PHASE1
Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure
- Status
- COMPLETED
- Phase
- PHASE2
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
- Status
- TERMINATED
- Phase
- PHASE2
Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
- Status
- COMPLETED
- Phase
- PHASE4
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- NA
Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
Velcade in Myelodysplastic Syndrome - Pilot Study
- Status
- TERMINATED
- Phase
- PHASE2
Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2